Callol L - Search Results

1

Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD.

Alvarez-Mon M, Miravitlles M, Morera J, Callol L, Alvarez-Sala JL. Alvarez-Mon M, et al. Among authors: callol l. Chest. 2005 Apr;127(4):1212-8. doi: 10.1378/chest.127.4.1212. Chest. 2005. PMID: 15821197 Clinical Trial.

2

[Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups].

Miravitlles M, Murio C, Morera J, Callol L, Alvarez-Sala JL, Alvarez-Mon M. Miravitlles M, et al. Among authors: callol l. Med Clin (Barc). 2008 May 17;130(18):688-92. doi: 10.1157/13120769. Med Clin (Barc). 2008. PMID: 18501139 Clinical Trial. Spanish.

3

Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón).

Prieto A, Reyes E, Bernstein ED, Martinez B, Monserrat J, Izquierdo JL, Callol L, de LUCAS P, Alvarez-Sala R, Alvarez-Sala JL, Villarrubia VG, Alvarez-Mon M. Prieto A, et al. Among authors: callol l. Am J Respir Crit Care Med. 2001 Jun;163(7):1578-83. doi: 10.1164/ajrccm.163.7.2002015. Am J Respir Crit Care Med. 2001. PMID: 11401877 Clinical Trial.

4

Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.

Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M, Callol L. Villegas FR, et al. Among authors: callol l. Lung Cancer. 2002 Jan;35(1):23-8. doi: 10.1016/s0169-5002(01)00292-6. Lung Cancer. 2002. PMID: 11750709

5

NK cells in non-neoplastic lung tissue. Initial results.

Callol L, Coca S, Chillon MJ, Villegas F, Moreno-Muro F, Gomez-Terreros FJ. Callol L, et al. Respir Med. 1995 Jan;89(1):77. doi: 10.1016/0954-6111(95)90079-9. Respir Med. 1995. PMID: 7708989 Free article. No abstract available.

6

Tumour markers in broncho-alveolar lavage.

Alvarez-Sala R, Blasco R, Callol L, Laguna R, Alvarez-Sala JL, Gomez de Terreros FJ. Alvarez-Sala R, et al. Among authors: callol l. Acta Oncol. 1989;28(2):290-1. doi: 10.3109/02841868909111266. Acta Oncol. 1989. PMID: 2736120 No abstract available.

7

Arteriolar pulmonary resistance and ventilatory equivalent for oxygen.

Callol L, Villegas FR, Calderon J, Chillon MJ, Gómez-Terreros FJ. Callol L, et al. Respir Med. 1993 Feb;87(2):158. doi: 10.1016/0954-6111(93)90151-o. Respir Med. 1993. PMID: 8497688 No abstract available.

8

An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.

Prados C, Alvarez-Sala R, Gómez de Terrero J, Callol L, García Río F, Gómez Carrera L, Gomez de Terreros Caro J, Alvarez-Sala JL, Espinós D, Villamor J. Prados C, et al. Among authors: callol l. Jpn J Clin Oncol. 2000 May;30(5):215-20. doi: 10.1093/jjco/hyd052. Jpn J Clin Oncol. 2000. PMID: 10857498

9

[Diagnostic accuracy of semiquantitative analysis of positron emission tomography in radiologically indeterminate lung lesions].

Ruiz-Hernández G, González A, de Juan R, Verea H, Callol LM, Domper M, Suárez M, Lapeña L, Montz R, Carreras Delgado JL. Ruiz-Hernández G, et al. Among authors: callol lm. Rev Esp Med Nucl. 2002 Nov-Dec;21(6):403-9. doi: 10.1016/s0212-6982(02)72116-2. Rev Esp Med Nucl. 2002. PMID: 12425887 Spanish.

10

How to express tumor markers in bronchoalveolar lavage.

Gómez de Terreros Caro FJ, Alvarez-Sala R, Prados MC, Callol L, Gómez de Terreros Sánchez FJ, Villamor J. Gómez de Terreros Caro FJ, et al. Among authors: callol l. Int J Biol Markers. 2004 Jan-Mar;19(1):67-71. Int J Biol Markers. 2004. PMID: 15077929 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results